2-CS2-1
世界初デジタルメディスンについて
First FDA-approved Digital Medicine
〇倉橋伸幸1
NobuyukiKurahashi1
1大塚ファーマシューティカル D&C
1Otsuka Pharmaceutical Development & Commercialization Inc
It is well known that there is a high correlation between the relapse rate of mental disorders such as schizophrenia and medication adherence. Therefore, it is possible to prevent acute exacerbation of symptoms and to prevent re-hospitalization by continuing taking medication. On the other hand, it is also well known that it is very difficult for patients to keep taking medication every day for various reasons - patients don't believe drugs work, troublesome side effects or lack of insights on their diseases.
It is very important to understand their medication adherence and their reasons non-adherence, we should provide enough support for them to continue their medication, raise awareness of their disease and educate them on the necessity and importance of taking their medication. However, it is not easy for healthcare professionals, care givers and families to know how good or bad the patient's adherence is because it depends on the patients self-report or checking of the residual medicine which is not always accurate. As a result, when the patient relapses, it is challenging for the healthcare professional to determine whether it comes from poor adherence or whether the medication is effective.
Otsuka and Proteus Digital Health (hereinafter referred to as "Proteus") developed the first digital medicine "Abilify MyCite" that can measure medication adherence. It embeds a very small sensor developed by Proteus into an antipsychotic Abilify tablet marketed by Otsuka. When a patient swallows tablets, a chip emits a signal in the stomach and it is captured by a small patch which sticks to the patient's abdomen and this is recorded. The patch transmits adherence information to the patient's smartphone as well as capturing activity and rest from sensors on the patch. The transmitted information is captured on both the patient's phone as well as shared with healthcare professionals, caregivers and families with the patients' consent. Based on this information, healthcare professionals can measure the condition of the patient and assess the risk if there is a sign of recurrence such as poor adherence or abnormal sleep pattern, then take the appropriate intervention.
In November 2017, Otsuka received approval from the US Food and Drug Administration (FDA) for this world's first digital medicine. We will continue to contribute to patients, families and healthcare professionals through not only medicines as a pharmaceutical company but also to provide important medical information and solutions for better patient health.
2-CS2-2
製薬業界におけるデジタルヘルス分野のオープンイノベーション
Open innovation for Digital Health in Pharmaceutical industry
〇菊池紀広1、高橋俊一1
NorihiroKikuchi1, ShunichiTakahashi1
1バイエル薬品株式会社オープンイノベーションセンター
1Open Innovation Center Japan, Bayer Yakuhin, Ltd.
Digital Health has emerged as innovative technologies to transform healthcare industry. Many Digital Health solutions are being developed to solve the healthcare problems using artificial intelligence (AI), Internet of things (IoT), wearable devices etc. Pharmaceutical companies are also accelerating the development of Digital Health solutions to optimize their value chain from drug discovery to post marketing, and to improve patients' quality of life. Successful implementation of these solutions requires new competencies such as agile development and digital technological expertise, and open innovation is an essential part of fostering the competencies. At the presentation, we will share our digital activities and ‘G4A' which is an open innovation program for Digital Health.
2-CS2-3
医薬品業界におけるデジタル化の新潮流
New trends in digitization in the pharmaceutical industry
〇大塚勝1
MasaruOtsuka1
1武田薬品工業デジタルユニット デジタル アクセラレーター ジャパンヘッド
1Takeda Pharmaceutical
Recently, "digitization", a kind of buzz word, has been widely used in many industries. In addition, it has been estimated that "disruptive changes" would be induced by such a wave of digitization. The current trend gives me a lot of questions; The media has reported to use of digital technology advances in the health care industry, but what about? The media has reported that information technology (IT) companies have entered the healthcare industry, or what? How Google, Apple, Facebook, and Amazon (GAFA) have entered the healthcare industry? The changes in external environments have made sense for us in the health care sector?
In this symposium, I would like to disclose my understanding of "Implications of digital evolution for the pharmaceutical industry and future prospects", referring to the digital changes in other industries.
2-CS2-4
製薬企業とCross-industry collaboration:FusionとFuture
Pharmaceutical Company and Cross-industry collaboration:Fusion & Future
〇木野ゆりか1
YurikaKino1
1田辺三菱製薬㈱フューチャーデザイン部
1Future Design Dept. Mitsubishi Tanabe Pharma Corporation
In 2017 Mitsubishi Tanabe Pharma established the Future Design Department. The Future Design Department is advancing a transformation to a data-driven company with a view to the use of Big Data, AI, IoT, Digital Medicine and other digital technologies with the objective of fostering "disruptive innovation" in the pharmaceutical business. We are working to create new methods that transcend the pharmaceutical industry's conventional pharmaceutical categories. Mitsubishi Tanabe Pharma is promoting open innovation with some universities and companies of different industries about issues with impact within the drug discovery value chain.
For example, Mitsubishi Tanabe Pharma and Hitachi have initiated collaborative creation for improving the efficiency of clinical trials using Hitachi's advanced digital technology such as AI.
In another example, in 2018, we will start an accelerator program. With the key words of "creating the future of healthcare" we will build a business model that transcends the conventional pharmaceutical business framework and strive to contribute to the happiness and health of patients and those around them.
In order to expand our business "around the pill" and "beyond the pill", we are working on the challenge of creating new value in the fields of medicine and healthcare through cross-industry collaboration with cutting edge technologies and different industries. In this presentation, we would like to introduce the above contents along the case of Future Design Department in Mitsubishi Tanabe Pharma.